Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 7/20 | 0.87 |
| ▸ | GAA | P10253 | 7/20 | 0.87 |
| ▸ | SI | P14410 | 7/20 | 0.87 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.87 |
| ▸ | IDH1 | O75874 | 4/20 | 0.87 |
| ▸ | FASN | P49327 | 4/20 | 0.87 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.87 |
| ▸ | RELA | Q04206 | 3/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.87 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.73 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.73 |
| ▸ | PGAM1 | P18669 | 3/20 | 0.73 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KDM1A | O60341 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929664 | 1.00 | MGAM (0.87) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL30830372 | 0.93 | MGAM (0.85) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL29929598 | 0.93 | MGAM (1.00) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL3742268 | 0.93 | MGAM (1.00) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL3750432 | 0.93 | MGAM (0.85) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL29974819 | 0.93 | MGAM (1.00) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL30830383 | 0.91 | MGAM (0.79) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL27311464 | 0.91 | MGAM (0.79) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL30830382 | 0.91 | MGAM (0.79) | MGAMGAASIMGAM2IDH1 | |
| SCHEMBL20620648 | 0.90 | MGAM (0.75) | MGAMGAASIMGAM2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| US-8461360-B2 | Process for producing γ -mangostin | LAILA NUTRACEUTICALS (US) | 2013-06-11 | — | — | US | claimed |
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | LAILA NUTRACEUTICALS (IN) | 2010-11-18 | — | — | US | claimed |
| WO-2009093259-A2 | A PROCESS FOR PRODUCING γ-MANGOSTIN | GOKARAJU GANGA RAJU (IN) | 2009-07-30 | — | — | WO | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-8461360-B2 | Process for producing γ -mangostin | LAILA NUTRACEUTICALS (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | LAILA NUTRACEUTICALS (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009093259-A2 | A PROCESS FOR PRODUCING γ-MANGOSTIN | GOKARAJU GANGA RAJU (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | SOST, CYP51A1, GNMT | MGAM 39/4885GAA 342/4885SI 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.